Christian Beaulieu

USPTO Granted Patents = 11 (Patent Applications = 3)

CIPO Patents = 1

EPO Patents = 7 (Patent Applications = 6)

Average Co-Inventor Count = 8.0

ph-index = 4

Forward Citations = 61(Granted Patents)

Company Filing History:

Merck Sharp + Dohme Corp.

patents

3 out of 76

Merck Frosst Canada & Co.

patents

where one patent can have more than one assignee

Years Active: 2006-2018

Loading Chart...

11 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 9994587 - HIV protease inhibitors (2018-06-12),

2. 9834526 - HIV protease inhibitors (2017-12-05),

3. 9737545 - HIV protease inhibitors (2017-08-22),

4. 9586931 - Triazolyl derivatives as Syk inhibitors (2017-03-07),

5. 9487504 - Imidazolyl analogs as syk inhibitors (2016-11-08),

6. 9315475 - HIV protease inhibitors (2016-04-19),

7. 9242984 - Pyrazolyl derivatives as Syk inhibitors (2016-01-26),

8. 8642799 - Cysteine protease inhibitors for the treatment of parasitic diseases (2014-02-04),

9. 7622502 - Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitors (2009-11-24),

10. 7144913 - Dihydropyrrolo[1,2-a]indole and tetrahydropyrido[1,2-a]-indole derivatives as prostaglandin d2 receptor antagonists (2006-12-05),

11. 7019022 - Substituted tetrahydrocarbazole and cyclopentanoindole derivatives (2006-03-28),

Title: Innovations in HIV Treatment: The Contributions of Inventor Christian Beaulieu

Introduction: Christian Beaulieu, a prolific inventor based in Laval, CA, has made significant strides in the field of pharmaceutical innovations, particularly in HIV treatment. With a total of 11 patents to his name, his groundbreaking work focuses on the development of advanced HIV protease inhibitors.

Latest Patents: Among his most recent patents are innovative compounds in the form of 2,6-morpholine derivatives and 2,5,6-substituted morpholine derivatives. These inventions are aimed at inhibiting HIV protease and replication, providing methods for both the prophylaxis and treatment of HIV infections. Additionally, these compounds contribute to delaying the onset or progression of AIDS. The inventions include the formulation of these compounds as ingredients in pharmaceutical compositions, which may be combined with other antivirals, immunomodulators, antibiotics, or vaccines.

Career Highlights: Throughout his career, Christian Beaulieu has worked with leading pharmaceutical companies, including Merck Canada Inc. and Merck Sharp & Dohme Corporation. His expertise in the development of antiviral agents has positioned him as a key figure in the ongoing battle against HIV.

Collaborations: Christian has collaborated with talented coworkers such as Vouy Linh Truong and Daniel Guay. Their combined expertise has undoubtedly contributed to the success of his innovative projects and patents.

Conclusion: Christian Beaulieu's contributions to the field of HIV treatment through his numerous patents underscore his role as a vital inventor in the pharmaceutical industry. His ongoing research and innovations continue to pave the way for more effective HIV therapies, helping to improve the lives of countless individuals affected by the virus.

This text is generated by artificial intelligence and may not be accurate.